FDA approves Grifols’ Xembify to treat primary immunodeficiencies

FDA approves Grifols’ Xembify to treat primary immunodeficiencies

Source: 
Pharmaceutical Business Review
snippet: 

Plasma-derived medicines producer Grifols has secured approval from the US Food and Drug Administration (FDA) for its Xembify, a new 20% subcutaneous immunoglobulin solution, to treat primary immunodeficiencies.